Division of Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Respiratory Oncology Unit, University Hospital KU Leuven, Leuven, Belgium.
Ann Oncol. 2020 Feb;31(2):191-201. doi: 10.1016/j.annonc.2019.10.026. Epub 2019 Dec 20.
The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of early and locally-advanced non-small-cell lung cancer (NSCLC) was published in 2017, and covered the diagnosis, staging, management and treatment of both early stage I and II disease and locally-advanced stage III disease. At the ESMO Asia Meeting in November 2018, it was decided by both the ESMO and the Korean Society of Medical Oncology (KSMO) to convene a special face-to-face guidelines meeting in 2019 in Seoul. The aim was to adapt the ESMO 2017 guidelines to take into account potential differences related to ethnicity, cancer biology and standard practices associated with the treatment of locally-advanced, unresectable NSCLC in Asian patients. These guidelines represent the consensus opinions reached by those experts in the treatment of patients with lung cancer who represented the oncology societies of Korea (KSMO), China (CSCO), India (ISMPO), Japan (JSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence, and it was independent of both local current treatment practices and the treatment availability and reimbursement situations in the individual participating Asian countries.
欧洲肿瘤内科学会（ESMO）最新版的《早期和局部晚期非小细胞肺癌（NSCLC）诊断、治疗和随访临床实践指南》于 2017 年发布，涵盖了 I 期和 II 期疾病的诊断、分期、管理和治疗，以及局部晚期 III 期疾病。在 2018 年 11 月的 ESMO 亚洲会议上，ESMO 和韩国肿瘤内科学会（KSMO）决定于 2019 年在首尔召开一次特别的面对面指南会议。目的是调整 ESMO 2017 年指南，以考虑与种族、癌症生物学以及与亚洲局部晚期不可切除 NSCLC 患者治疗相关的标准实践相关的潜在差异。这些指南代表了来自韩国（KSMO）、中国（CSCO）、印度（ISMPO）、日本（JSMO）、马来西亚（MOS）、新加坡（SSO）和中国台湾（TOS）肿瘤学会的肺癌治疗专家的共识意见。投票是基于科学证据的，既不受当地当前治疗实践的影响，也不受各参与亚洲国家的治疗可及性和报销情况的影响。
Zotero 插件